Click on headlines below to download research

FDA issues CCP-07 complete response letter
Vernalis | 24/04/2017

FDA has issued a complete response letter (CRL) to Vernalis’ CCP-07 NDA following its 20 April PDUFA date, outlining questions that need to be addressed…

Positive Tuzistra trends
Vernalis | 15/03/2017

Investment into addressing barriers to higher Tuzistra XR prescribing is starting to translate into higher prescription (Rx) rates. Mid-way through the…

Advancing towards a commercial portfolio
Vernalis | 05/01/2017

FDA acceptance of the CCP-08 NDA (setting a 4 August 2017 PDUFA date) advances Vernalis towards its goal of building a speciality US franchise of extended…